Alzamend Neuro has partnered with Massachusetts General Hospital to conduct a pioneering Phase II clinical trial of its AL001 treatment for PTSD, led by Dr. Ovidiu Andronesi.
Author: Ecem Efe (Ecem Efe)
Post
Hong Kong Stocks Surge as Tech Shares Rally Ahead of Earnings Season
Hong Kong stocks rose on Monday, led by a tech rally and driven by investor anticipation of upcoming earnings and potential U.S. interest rate cuts.
Post
Rocket Lab Stock – Rocket Lab Sets Sights on Mars with Groundbreaking ESCAPADE Mission
Rocket Lab is making strides in space exploration with its cost-effective ESCAPADE mission to Mars, potentially redefining the space industry.
Post
Nvidia Stock Surges: Retakes 50-Day Moving Average Amid AI Chip Demand
Nvidia stock has rebounded, retaking the 50-day moving average and gaining 16% this week amid rising AI chip demand and recent market volatility.
Post
Mars Stock – Mars Acquires Kellanova in $30 Billion Deal, Expanding into Salty Snacks
Mars is set to acquire Kellanova for nearly $30 billion, significantly expanding its brand portfolio into the salty snack sector, including notable brands like Pringles and Cheez-It.
Post
Mining Stocks – Indian Mining Stocks Plunge After Supreme Court Ruling on Royalty Payments
Indian mining stocks, including NMDC, Tata Steel, and Vedanta, fell sharply after the Supreme Court ruled that states could collect backdated royalties on mineral-bearing lands, overturning previous judgments and allowing for staggered payments over 12 years.
Post
BNS Stock Price – Bank of Nova Scotia Stock Receives Mixed Ratings: Analysts Update Price Targets
Bank of Nova Scotia (BNS) stock has a "Reduce" consensus rating, with a current price of C$61.49, recent earnings exceeding estimates, and a dividend yield of 6.90%, while analysts have set various price targets ranging from C$65.00 to C$71.00.
Post
August 12 Stock News – Motisons Jewellers’ Stock Surges Ahead of Upcoming Fundraising Meeting
Motisons Jewellers' share price rose by 2% to ₹173.90 as the company prepares for a board meeting on August 14, 2024, to discuss a significant fundraising proposal.
Post
NKLA Stock – Nikola (NKLA) Stock Rises After Surpassing Q2 Earnings Expectations
Nikola (NKLA) saw its shares rise following a Q2 earnings report that beat expectations, while the company continues to address challenges in its BEV business and faces significant hurdles despite positive analyst outlooks.
Post
Microsoft Stock -Microsoft’s Market Cap Takes a Hit: Is Now the Time to Buy Despite Cloud Concerns?
Microsoft's stock has declined 13.5% recently due to weaker-than-expected cloud results, but its strong long-term potential driven by AI investments and a diversified business portfolio makes it a buying opportunity for patient investors.
